Comorbidities Articles

Discover more about the comorbidities of NASH / NAFLD through articles on NASH commentary content ▶ from a study obtained from expert doctors worldwide.

Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Authors: Younossi ZM et al.
Published in Journal of Hepatology (November 2023)
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
Read MoreSurveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Cardiovascular Disease in MASLD Patients: Mitigating Risks

Authors: Mellemkjær A et al.
Published in European Journal of Internal Medicine (November 2023)
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease (NAFLD)’s exclusionary nomenclature.
Read MoreCardiovascular Disease in MASLD Patients: Mitigating Risks

Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Authors: Pais R, Cariou B, Noureddin M et al.
Published in Journal of Hepatology (September 2023)
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Read MoreManaging Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum

Are Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?

Authors: Bouriser J, Canivet CM, Costentin C et al.
Published in Clinical Gastroenterology and Hepatology (May 2023)
Recent literature on non-alcoholic fatty liver disease (NAFLD) has sought to characterise its bidirectional association with type 2 diabetes mellitus (T2DM).
Read MoreAre Non-invasive Tools Less Accurate in NAFLD Patients With Type 2 Diabetes?

Understanding Nash: Symptoms, Detection, And Treatment

Authors: Basu M, Noureddin M, Clark JM
Published in Mayo Clinic Proceedings (September 2022)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Read MoreUnderstanding Nash: Symptoms, Detection, And Treatment

An exploration of MAFLD’s clinical utility

Authors: Ramírez-Mejía MM, Xingshun Q, Abenavoli L et al
Published in Annals of Hepatology (July 2023)
In 2020, a group of international experts proposed that non-alcoholic fatty liver disease (NAFLD) be renamed to metabolic dysfunction-associated fatty liver disease (MAFLD).
Read MoreAn exploration of MAFLD’s clinical utility

NAFLD and New-Onset Heart Failure: What is the Link?

Authors: Inciardi RM, Mantovani A and Targher G
Published in Current Heart Failure Reports (July 2023)
Non-alcoholic fatty liver disease (NAFLD) and congestive heart failure (HF) represent global public health concerns.
Read MoreNAFLD and New-Onset Heart Failure: What is the Link?

Adipose tissue insulin resistance and fibrosis stage in NASH

Authors: Kalavalapalli S, Leiva EG, Lomonaco R et al.
Published in Journal of Clinical Endocrinology and Metabolism (April 2023)
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
Read MoreAdipose tissue insulin resistance and fibrosis stage in NASH

Adverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?

Authors: Linge J, Nasr P, Sanyal AJ et al.
Published in JHEP Reports: Innovations in Hepatology (December 2022)
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
Read MoreAdverse Muscle Composition in NAFLD: An Association with All-Cause Mortality?

NAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities

Authors: Shaheen M, Schrode KM, Tedlos M et al.
Published in Frontiers in Physiology (February 2023)
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.
Read MoreNAFLD, Race and Gender in Prediabetic and Diabetic Patients in the US: Detecting Disparities

The Power of PPARs in NASH-associated Microvascular Dysfunction

Authors: Guixé-Muntet S, Biquard L, Szabo G et al.
Published in Alimentary Pharmacology and Therapeutics (July 2022)
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD).
Read MoreThe Power of PPARs in NASH-associated Microvascular Dysfunction

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES